Drugs / H001
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06963320 | Jan → Jun 2025 overdue | cardiovascular disorder | Livzon Pharmaceutical Group Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06963320 ↗ |
| Known as | H001 Capsule | “H001 Capsule, 50 mg/capsule, 200 mg orally once daily for 10-14 days.” NCT06963320 ↗ |
| Route | Oral | “200 mg orally once daily” NCT06963320 ↗ |